SWS Partners Takes $2.90 Million Position in DexCom, Inc. $DXCM

SWS Partners bought a new position in DexCom, Inc. (NASDAQ:DXCM) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 43,005 shares of the medical device company’s stock, valued at approximately $2,896,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Geode Capital Management LLC raised its position in DexCom by 0.4% in the 4th quarter. Geode Capital Management LLC now owns 11,006,183 shares of the medical device company’s stock valued at $727,842,000 after purchasing an additional 42,411 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of DexCom by 6.9% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,999,057 shares of the medical device company’s stock worth $530,897,000 after purchasing an additional 516,526 shares during the last quarter. Norges Bank acquired a new stake in shares of DexCom in the fourth quarter valued at $483,356,000. Invesco Ltd. increased its stake in shares of DexCom by 14.8% in the fourth quarter. Invesco Ltd. now owns 5,315,367 shares of the medical device company’s stock valued at $352,781,000 after buying an additional 686,228 shares in the last quarter. Finally, CIBC Private Wealth Group LLC raised its holdings in shares of DexCom by 7.6% in the fourth quarter. CIBC Private Wealth Group LLC now owns 3,128,114 shares of the medical device company’s stock valued at $207,613,000 after buying an additional 220,313 shares during the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Stock Down 1.9%

NASDAQ:DXCM opened at $89.75 on Friday. The company has a quick ratio of 1.43, a current ratio of 1.73 and a debt-to-equity ratio of 0.47. DexCom, Inc. has a 12-month low of $54.11 and a 12-month high of $91.96. The stock’s fifty day simple moving average is $76.08 and its 200-day simple moving average is $70.36. The firm has a market capitalization of $33.87 billion, a P/E ratio of 35.47, a P/E/G ratio of 1.54 and a beta of 1.41.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, July 30th. The medical device company reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.61 by $0.09. DexCom had a return on equity of 35.94% and a net margin of 20.12%.The business had revenue of $1.31 billion during the quarter, compared to the consensus estimate of $1.29 billion. During the same quarter in the prior year, the company posted $0.48 earnings per share. The firm’s revenue was up 13.1% on a year-over-year basis. Equities research analysts expect that DexCom, Inc. will post 2.64 earnings per share for the current year.

Analysts Set New Price Targets

DXCM has been the topic of several research reports. Canaccord Genuity Group set a $90.00 price target on shares of DexCom and gave the stock a “buy” rating in a research report on Monday, August 3rd. Wall Street Zen cut shares of DexCom from a “strong-buy” rating to a “buy” rating in a research report on Sunday, May 10th. BTIG Research reaffirmed a “buy” rating and issued a $90.00 target price (up from $80.00) on shares of DexCom in a research note on Friday, July 31st. Mizuho upped their target price on shares of DexCom from $90.00 to $95.00 and gave the stock an “outperform” rating in a research report on Friday, July 31st. Finally, Stifel Nicolaus set a $95.00 price target on shares of DexCom and gave the company a “buy” rating in a research note on Friday, July 31st. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $88.71.

Insider Buying and Selling

In related news, insider Kevin R. Sayer sold 26,759 shares of DexCom stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $72.00, for a total transaction of $1,926,648.00. Following the transaction, the insider owned 382,482 shares of the company’s stock, valued at $27,538,704. This trade represents a 6.54% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Jon Brown sold 1,700 shares of DexCom stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $75.55, for a total transaction of $128,435.00. Following the transaction, the executive vice president directly owned 106,353 shares in the company, valued at $8,034,969.15. The trade was a 1.57% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 99,794 shares of company stock valued at $7,373,321 over the last 90 days. 0.28% of the stock is owned by corporate insiders.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.